Ceritinib

Key Product Details

Product Description

Ceritinib is a highly potent anaplastic lymphoma kinase (ALK) inhibitor (IC₅₀ = 0.2 nM). Also displays potent inhibition of insulin receptor (IR), insulin-like growth factor receptor 1 (IGF1R), serine/threonine-protein kinase STK22D and FLT3 (IC₅₀ values are 7, 8, 23 and 60 nM, respectively). Inhibits tumor growth in Karpas299 and H2228 rat xenograft models.

Product Specifications for Ceritinib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ceritinib

The following data is based on the product molecular weight 558.14.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	35.83 mL	179.17 mL	358.33 mL
0.25 mM	7.17 mL	35.83 mL	71.67 mL
0.5 mM	3.58 mL	17.92 mL	35.83 mL
2.5 mM	0.72 mL	3.58 mL	7.17 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Marsilje Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J.Med.Chem. 2013 PMID: 23742252

Product Documents for Ceritinib